Skip to content
10-K

Annual Report

Cantabio Pharmaceuticals Inc.

0001424884-17-000049

← back to feed
Filed
Jun 30, 2017 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2017 · Mar 31, 2017 26.81M sh
Operating Cash Flow FY 2017 · Mar 31, 2016 −$564.66K
Current Liabilities FY 2017 · Mar 31, 2016 $421.89K
Total Liabilities FY 2017 · Mar 31, 2016 $421.89K
Current Assets FY 2017 · Mar 31, 2016 $52.11K
Total Assets FY 2017 · Mar 31, 2016 $52.11K
Sga Expense FY 2017 · Mar 31, 2016 $691.78K
Rd Expense FY 2017 · Mar 31, 2016 $149.16K
Net Income FY 2017 · Mar 31, 2016 −$751.33K
Cash And Equivalents FY 2017 · Mar 31, 2015 $209
Stockholders Equity restated FY 2017 · Mar 31, 2015 −$218.46K